![](https://library.celltelligence.com/wp-content/uploads/2021/04/AACR_Announcement.png)
$0
Latest NK Cell Therapy Advances Discussed in a Panel Session; Fate Tx Presents Preclinical Updates for Two iPSC-derived CAR-NKs; AACR 2021 Day 5
On the fifth day of AACR 2021 Week I, two key preclinical CAR-NK updates were reported from Fate Therapeutics, while the latest NK cell engineering approaches were reviewed during a panel discussion. Below, Celltelligence provides insights and context for each presentation.